Pharmaceuticals (Nov 2024)

Pharmacological Evaluation of the Traditional Brazilian Medicinal Plant <i>Monteverdia ilicifolia</i> in Gastroesophageal Reflux Disease: Preliminary Results of a Randomized Double-Blind Controlled Clinical Trial

  • Maitê Scherer da Silva,
  • Rebeca Vargas Antunes Schunck,
  • Maicon Pereira Moraes,
  • Giana Blume Corssac,
  • Gabriela Meirelles,
  • Sara Elis Bianchi,
  • Leonardo Vieira Targa,
  • Valquiria Bassani,
  • Marcelo Rodrigues Gonçalves,
  • Caroline Dani,
  • Ionara Rodrigues Siqueira

DOI
https://doi.org/10.3390/ph17111559
Journal volume & issue
Vol. 17, no. 11
p. 1559

Abstract

Read online

Background/Objectives: The present work aimed to compare the effects of the standardized dry extract from the leaves of Monteverdia ilicifolia, popularly known as “espinheira-santa”, with omeprazole in the management of dyspepsia related to gastroesophageal reflux disease (GERD). Methods: A double-blind, randomized, non-inferiority and double-dummy clinical trial was conducted. In total, 86 patients with GERD symptoms were randomized into three groups: Omeprazol (20 mg), M. ilicifolia (400 mg), or M. ilicifolia (860 mg). Capsules were provided by SUSTENTEC®, Pato Bragato, Brazil. It was requested that the participants take three capsules before breakfast and dinner for 4 weeks. Clinical outcomes were obtained at the beginning and end of the study, with GERD symptoms (QS-GERD), the impact of heartburn symptoms on quality of life (HBQOL), and medical records. Results: Overall, 75.6% of the participants showed adherence without any differences among the experimental groups. All groups had significant reductions in both QS-GERD and HBQOL scores. Omeprazole and 400 and 860 mg of M. ilicifolia decreased the QS-GERD total scores at the endpoint compared to the baseline (Chi-square = 129.808; p p p M. ilicifolia at a dosage of 400 or 860 mg are non-inferior to omeprazole, a proton pump inhibitor.

Keywords